Clinical Report: Optimized Dosing of Brentuximab Vedotin Enhances Outcomes

Overview

This study evaluates the efficacy and safety of brentuximab vedotin (BV) in combination with an A-AVD-like regimen compared to an ABVD-like regimen in Chinese patients with classic Hodgkin lymphoma (cHL).

Background

Classic Hodgkin lymphoma (cHL) is a highly curable malignancy, yet some patients experience poor outcomes with standard regimens like ABVD. The incorporation of targeted therapies such as brentuximab vedotin (BV) aims to enhance treatment efficacy while mitigating associated toxicities.

Data Highlights

Key Findings

• The A-AVD group had a higher proportion of elderly patients (≥60 years) compared to the ABVD group (25.5% vs. 9.4%, p = 0.002).
• First-evaluation complete response rates were similar between ABVD and A-AVD (CR: 69.3% vs. 72.5%, p = 0.549).
• Overall progression-free survival (PFS) and overall survival (OS) showed no significant differences between the two regimens (PFS p=0.489; OS p = 0.230).
• In patients with Ann Arbor stage III-IV, a sufficient dose of BV (≥1.15 mg/kg) significantly improved PFS compared to a reduced dose (<1.15 mg/kg) (2-year PFS 91.7% vs. 58.7%; p=0.036).
• The A-AVD group exhibited a higher rate of peripheral neuropathy (47.1% vs. 5.2%, p < 0.001).
• Incidences of grade 3–4 neutropenia were comparable between the two groups (17.7% in ABVD vs. 19.6% in A-AVD, p = 0.751).

Clinical Implications

Clinicians should be aware of the increased risk of peripheral neuropathy with the A-AVD regimen.

Conclusion

This study presents findings on the dosing of brentuximab vedotin in patients with classic Hodgkin lymphoma.

Related Resources & Content

1. The ASCO Post, Four-Drug Regimen Induces High Complete Response Rate in Early-Stage Classical Hodgkin Lymphoma
2. The ASCO Post, Brentuximab Vedotin Improves Response Rates to ABVD in Hodgkin Lymphoma
3. The ASCO Post, Brentuximab Vedotin Shows Antitumor Activity in Patients With Relapsed Peripheral T-Cell Lymphoma
4. Hodgkin lymphoma: EHA Clinical Practice Guidelines for diagnosis, treatment, and follow‐up - PMC
5. Nivolumab-AVD in Advanced Stage Classic Hodgkin Lymphoma - PMC
6. The ASCO Post — Improved Progression-Free Survival With Brentuximab Vedotin After Transplantation in Hodgkin Lymphoma Patients
7. Hodgkin lymphoma: EHA Clinical Practice Guidelines for diagnosis, treatment, and follow‐up - PMC
8. Nivolumab-AVD in Advanced Stage Classic Hodgkin Lymphoma - PMC
9. ADCETRIS (brentuximab vedotin) Highlights of Prescribing Information